ArticleClinical ophthalmology (Auckland, N.Z.)2026
Effectiveness and Safety of Combined Ab-Interno Canaloplasty and Microstent Implantation in Severe Glaucoma - A Retrospective Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of ab-interno canaloplasty combined with microstent implantation in patients with severe glaucoma. Patients and Methods: This retrospective study included patients with severe glaucoma (mean age 74.6±8.7 years), predominantly primary open-angle (90%). All eyes underwent combined ab-interno canaloplasty using the iTrack (Nova Eye Medical) with concurrent Hydrus Microstent (Alcon) implantation during cataract surgery. The primary outcome measures were intraocular pressure (IOP), number of glaucoma medications, visual field mean deviation (VFMD), postoperative complications. Results: Sixty-nine eyes of 56 patients were followed for mean 27.9±13.8 months. Mean IOP decreased from 17.8±6.3 at baseline to 15.5±4.7 mmHg at last follow-up (p=0.012), and mean number of medications decreased by 47%, from 2.10±1.1 to 1.12±1.2 (p<0.001). Medication-free eyes increased from 7% at baseline to 43% at last follow-up. Among eyes that were on 3 and 4 medications preoperatively (n=17; n=7), the number of medications significantly decreased by 53% (p<0.001) and 57% (p=0.002) at last follow-up, while IOP remained stable. Eyes with baseline IOP >18 mmHg (n=21) experienced a significant mean IOP reduction of 9.8 mmHg (from 24.8±6.7 to 15.0±4.6 mmHg; -40%, p<0.001). No intraoperative or postoperative complications were reported; 6 eyes (9%) required additional glaucoma procedures during follow-up. Conclusion: Combining ab-interno canaloplasty with Hydrus Microstent implantation during cataract surgery resulted in modest but sustained reductions in intraocular pressure and glaucoma medication burden, with a favorable safety profile. However, postoperative IOP frequently remained above levels required for very low target pressures. These findings suggest that this mixed MIGS approach may be considered in carefully selected patients but should not be viewed as a substitute for traditional filtering surgery in advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.